Lataa...
Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide, a glucagon-like peptide 1 receptor agonist, showed potent cardioprotective effects with the mechanism is yet...
Tallennettuna:
| Julkaisussa: | Saudi Pharm J |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7132601/ https://ncbi.nlm.nih.gov/pubmed/32273812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsps.2020.03.002 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|